Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMT2FDC)

Drug Name
Desipramine Drug Info
Synonyms
Demethylimipramine; Desimipramine; Desimpramine; Desipramin; Desipramina; Desipraminum; Desmethylimipramine; Dezipramine; Dimethylimipramine; Methylaminopropyliminodibenzyl; Monodemethylimipramine; Norimipramine; Norpramine; Pentofran; Pertrofane; Sertofran; Desipramine Hcl; DMI 50475; DMI (pharmaceutical); Desipramina [INN-Spanish]; Desipramine (D4); Desipramine (INN); Desipramine [INN:BAN]; Desipraminum [INN-Latin]; Norpramin (TN); Pertofrane (TN); ZERO/006017; N-(3-Methylaminopropyl)iminobibenzyl; (3-(10H,11H-Dibenzo[b,f]azepin-5-yl)propyl)methylamine; 10, 11-Dihydro-N-methyl-5H-dibez[b,f]azepine-5-propanamine; 10,11-Dihydro-5-(3-methylaminopropyl)-5H-dibenz(b,f)azepine; 3-(10,11-DIHYDRO-5H-DIBENZO[B,F]AZEPIN-5-YL)-N-METHYLPROPAN-1-AMINE; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine; 5-(gamma-Methylaminopropyl)iminodibenzyl
Therapeutic ClassAntidepressants
Cross-matching ID
PubChem CID
2995
ChEBI ID
CHEMBL72
CAS Number
CAS 50-47-5
TTD Drug ID
D01UTL
VARIDT Drug ID
DR00501
INTEDE Drug ID
DR0436
ACDINA Drug ID
D00179

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Steroid biosynthesis 2.75 0.00e+0 19/20 (95%) MSMO1;SQLE;LSS;...
PPAR signaling pathway 2.33 0.00e+0 66/74 (89.19%) HMGCS1;SCD;FADS2;...
Terpenoid backbone biosynthesis 2.19 0.00e+0 18/22 (81.82%) HMGCS1;IDI1;HMGCR;...
Biosynthesis of unsaturated fatty acids 2.17 0.00e+0 21/27 (77.78%) SCD;FADS1;FADS2;...
Fatty acid biosynthesis 2.06 0.00e+0 16/18 (88.89%) FASN;ACSL1;ACSL3;...
Cholesterol metabolism 1.88 1.01e-2 44/50 (88%) LDLR;LIPA;NPC1;...
Salivary secretion 1.87 8.65e-3 76/93 (81.72%) PLCB1;MUC5B;CALML3;...
Mineral absorption 1.86 1.01e-2 48/60 (80%) TF;HMOX1;SLC11A2;...
Primary bile acid biosynthesis 1.84 1.01e-2 15/17 (88.24%) AMACR;ACOX2;CH25H;...
Aldosterone synthesis and secretion 1.81 1.62e-2 85/98 (86.73%) LDLR;PLCB1;CALML3;...
Cushing syndrome 1.79 1.93e-2 125/155 (80.65%) LDLR;CDKN1B;PLCB1;...
Synthesis and degradation of ketone bodies 1.79 1.77e-2 9/10 (90%) HMGCS1;ACAT2
Type II diabetes mellitus 1.78 2.10e-2 42/46 (91.3%) ADIPOQ;PIK3R1;IRS2;...
Ascorbate and aldarate metabolism 1.74 2.74e-2 15/30 (50%) ALDH2;RGN;GUSB;...
Cortisol synthesis and secretion 1.73 3.10e-2 58/65 (89.23%) LDLR;PLCB1;ITPR3;...
Vibrio cholerae infection 1.72 3.34e-2 44/50 (88%) SLC12A2;KDELR3;ATP6V0E2;...
Ferroptosis 1.70 3.62e-2 36/41 (87.8%) ACSL1;ACSL3;TF;...
Synaptic vesicle cycle 1.68 4.15e-2 63/78 (80.77%) STXBP1;ATP6V0E2;CLTC;...
Valine, leucine and isoleucine degradation 1.67 4.36e-2 42/48 (87.5%) HMGCS1;ACAT2;AACS;...
Adipocytokine signaling pathway 1.67 4.29e-2 64/69 (92.75%) ACSL1;ACSL3;ADIPOQ;...
Nucleotide excision repair -1.67 4.62e-2 40/47 (85.11%) ERCC3;RFC3;RFC4;...
Ribosome -1.73 2.70e-2 113/158 (71.52%) RPSA;RPL5;RPL23A;...
Huntington disease -1.74 2.97e-2 233/306 (76.14%) TFAM;PSMA3;PSMD7;...
DNA replication -1.79 1.76e-2 34/36 (94.44%) MCM2;RNASEH1;RFC3;...
Mismatch repair -1.80 1.98e-2 22/23 (95.65%) EXO1;RFC3;RFC4;...
Proteasome -1.82 1.84e-2 44/46 (95.65%) PSMD11;PSMA6;PSMC1;...
Ribosome biogenesis in eukaryotes -1.82 1.98e-2 52/108 (48.15%) GNL3;POP4;REXO5;...
RNA transport -1.86 1.38e-2 128/186 (68.82%) TARDBP;EIF2B4;AAAS;...
Spliceosome -1.87 1.48e-2 101/150 (67.33%) SNW1;PPIH;CHERP;...
RNA polymerase -1.88 1.98e-2 23/31 (74.19%) POLR3G;POLR2H;POLR3E;...
Basal transcription factors -1.94 1.48e-2 37/45 (82.22%) TAF7;TAF9B;TBP;...
Tight junction -2.00 0.00e+0 130/169 (76.92%) DLG2;AMOT;CLDN18;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H